CDKN2AIP

Across TCGA pan-cancer cohorts, CDKN2AIP Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDKN2AIP data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CDKN2AIP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDKN2AIP expression acts as an unfavorable survival marker.

KIRC, HNSC, and ESCA are the cancer types where CDKN2AIP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.134	0.811	<.001	30	view →
HNSC	OS	Median	All	0.010	0.768	<.001	24	view →
ESCA	OS	Median	III,IV	0.130	0.574	.011	9	view →
CESC	OS	Median	All	0.180	0.595	.020	8	view →
LUSC	DFS	Median	All	0.165	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDKN2AIP–KIRC (OS)

Open the KIRC breakdown →